We wrote a survey last August of the possible use of cannabinoids in pharmaceutical intervention in glaucoma, a progressive degradation of retinal ganglion cells. Cannabinoids in general seem able to slow this degeneration, and to lower damaging intraocular pressure. 

One of them, cannabinol (CBN), was investigated at the University of British Columbia this year (Somvanshi RK, et al., Biolchim Biophys Acta Mol Basis Dis. 2022 Mar 1;1868(3):166325. doi: 10.1016/j.bbadis.2021.166325). The study aimed to evaluate its role, in vitro and in vivo, in neuroprotection and modulation of pressure, and its effects on extracellular matrix proteins.

In a mouse model, CBN was able to protect 661W retinal ganglion precursor-like cells from pressure-induced toxicity. In human trabecular meshwork cells, CBN attenuated changes in fibronectin α-smooth muscle actin, and mitogen-activated protein kinases, with and without transforming growth factor-beta 2-induced stress. Post-intravitreal CBN delivery in vivo also improved pattern electroretinogram amplitudes and reduced intraocular pressure in a rat episcleral vein laser photocoagulation model of glaucoma. 

DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome.